Supplemental Materials

[Appendix A. Medical Provider/Pharmacist Content Tool 2](#_Toc21950027)

[Appendix B. Index Patient/Sex Partner Content Tool 4](#_Toc21950028)

[Appendix C. EPT Informational Materials 5](#_Toc21950029)

[Appendix D. Evaluation Measure Results 11](#_Toc21950030)

[Appendix E. Inter-Rater Reliability for Design and Content Tools 14](#_Toc21950031)

[Appendix F. Document Rankings 16](#_Toc21950032)

# Appendix A. Medical Provider/Pharmacist Content Tool

*Directions: With the EPT informational material listed above, evaluate the content using the corresponding check list. Certain questions are relevant only for providers (DR).* ***The scoring system assigns 1 point for the presence of each attribute with a maximum score of 25.***

**I. EPT information for providers and pharmacists**

*Check Yes if the document entails the information below.*

|  |  |  |  |
| --- | --- | --- | --- |
| **Nr.** | **Question**  | **Yes** | **No** |
| 1 | Is the importance of **partner mgmt./referral** for STIs emphasized? |  |  |
| 2 | Is **Chlamydia** described? |  |  |
| 3 | Are the **long-term effects** of untreated Chlamydia described? |  |  |
| 4 | Is EPT/PDPT **defined**? |  |  |
| 5 | Is the **effectiveness**/are the benefits of EPT stated? |  |  |
| 6 | Does the document make any statement about **legality**? |  |  |
| 7 | Does the document make any statement about **liability**? |  |  |
| 8 | Is the **drug treatment** for Chlamydia described? |  |  |
|  |  *Azithromycin preferred Doxycycline preferred No preference* |  |  |
| 9 | Is “recent sexual partner” defined as a partner within the **past 60 days**? |  |  |
| 10 | Are **eligibility criteria** for EPT given? |  |  |
| 11 | Are **exclusion criteria** for EPT given, i.e. when is EPT not recommended? |  |  |
|  |  *STI/HIV coinfection Risk of IPV Child abuse risk Allergies* |  |  |
| 12 | Are directions given for the **delivery** **method** of EPT? |  |  |
|  |  *Prescription preferred Medication preferred No preference* |  |  |
| 13 | Are directions given for the **prescription instructions**? |  |  |
|  |  *Birthdate of partner Name of partner Other:* |  |  |
| 14 | Does the document make any reference to **the cost of** **EPT**, e.g. it’s free, will be covered by insurance, paid out of pocket, etc.? |  |  |

**II. Provider/Pharmacist communication with patient/partner**

*Check Yes if the document entails this guidance for patient/partner communication. Note: communication may vary if the partner fills the prescription at the pharmacy or if the patient picks up the prescription for the partner.*

|  |  |  |  |
| --- | --- | --- | --- |
| **Nr.** | **Question**  | **Yes** | **No** |
| 15 | Advise [patient to tell] partners to seek medical evaluation, e.g. **referral**. |  |  |
| 16 | Provide **written EPT instructions** for the patient/partner. |  |  |
| 17 | Provide **written information on allergies**/possible adverse reactions. |  |  |
| 18 | Advise the patient/partner to **abstain** from vaginal, anal and oral sex for 7 days post-treatment. |  |  |
| 19 | Advise the patient/partner be **retested** in 3 months. |  |  |
| 20 | Present (written or oral) at least one **STI prevention strategy**. |  |  |
|  |  *Testing with new partners Condoms Abstinence Counseling* |  |  |

**III. Additional content questions**

|  |  |  |  |
| --- | --- | --- | --- |
| **Nr.** | **Question**  | **Yes** | **No** |
| 21 | Are **adolescent populations** specifically mentioned? |  |  |
|  | Please summarize. |  |  |
| 22 | Are **MSM populations** specifically mentioned? |  |  |
|  | Please summarize. |  |  |
| 23 | Are **pregnant populations** specifically mentioned? |  |  |
|  | Please summarize. |  |  |
| 24 | Does the document mention a limit on **how many EPT** doses/prescriptions a doctor can provide to a patient? |  |  |
|  |  *Yes, limited No, no limit Not mentioned* |  |  |
| 25 | Are **endorsements of EPT** from medical associations and professional societies mentioned? |  |  |

# Appendix B. Index Patient/Sex Partner Content Tool

*Directions: With the EPT informational material listed above, evaluate the content using the corresponding check list. Certain questions are only relevant for patients (PAT).****The scoring system assigns 1 point for the presence of each attribute with a maximum score of 20.***

**I. Information for patients and partners**

*Check Yes if the document entails the information below.*

|  |  |  |  |
| --- | --- | --- | --- |
| **Nr.**  | **Question**  | **Yes**  | **No**  |
| 1  | Does it explain why the patient/partner is **receiving additional medication / prescription**, e.g. risk of exposure?  |   |   |
| 2  | Is **Chlamydia** described?  |   |   |
| 3  | Are the **symptoms** of Chlamydia described?  |   |   |
| 4  | Does it state that Chlamydia may be **asymptomatic**?  |   |   |
| 5  | Are the **long-term effects** of untreated Chlamydia described?   |   |   |
| 6  | Is EPT/PDPT **defined**?  |   |   |
| 7  | Is the **drug treatment** for Chlamydia described?  |   |   |
|  |  *Azithromycin described Doxycycline Described Both Described* |  |  |
| 8  | Is “recent sexual partner” defined as a partner within the **past 60 days**?  |   |   |
| 9  | Does the document make any reference to **the cost of** **EPT**, e.g. it’s free, will be covered by insurance, paid out of pocket, etc.?  |   |   |
| 10  | Does it include **information on** **allergies**/possible adverse reactions?  |   |   |
| 11  | Is there information about what to do **in the case of an adverse event**?  |   |   |
| 12  | Is it advised to **abstain** from vaginal, anal and oral sex for 7 days post-treatment?  |   |   |
| 13  | Is it advised to be to be **retested** in 3 months?  |   |   |
| 14  | Is at least one **STI prevention strategy** presented?  |   |   |
|  |  *Testing with new partners Condoms Abstinence Limit partners* |  |  |
| 15  | Does it include **sources**for STI-related health care information?  |   |   |
| 16  | Does it mention the risk of **intimate partner violence**?  |   |   |
| 17  | Does it entail directions/advice on **how to tell the partner** about the diagnosis?  |   |   |
| 18  | Does it entail directions/advice on **how to tell the partner** about EPT?  |   |   |
| 19  | Is there information about what to do in the case that the **partner refuses**totake medicine or seek STI testing?  |   |   |
| 20 | Does it describe what to expect when **picking up the prescription** at a pharmacy?   |  |  |
|  | Please summarize. |  |  |

# Appendix C. EPT Informational Materials

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **ID #** | **State/Territory** | **Document Title** | **Date\*** | **Audience** | **Format** | **Avg. Reading Level** | **Read-ability a** | **Design b** | **Content c**  | **Total Score** |
| AK\_1 | Alaska | Directions for Partners of Persons with Chlamydia | - | Sex Partners | Directions | 9.6 | 4 | 10 | 11.5 | 25.5 |
| AK\_2 | Alaska | Directions for Partners of Persons with Gonorrhea or Gonorrhea and Chlamydia | - | Sex Partners | Directions | 10.1 | 4 | 10 | 11 | 25 |
| AK\_3 | Alaska | Coaching Patients About Talking with Their Partner(s) | - | Medical Providers | Directions | 13.2 | 2 | 8.5 | 6.5 | 17 |
| AZ\_1 | Arizona | EPT in Arizona - You Can Treat the Partners - Postcard | - | Medical Providers | Postcard | 11.6 | 3 | 8.5 | 7.5 | 19 |
| AZ\_2 | Arizona | EPT in Arizona - You Can Treat the Partners - Poster | - | Medical Providers | Poster | 13.3 | 2 | 10.5 | 7.5 | 20 |
| AZ\_3 | Arizona | EPT Fact Sheet for Pharmacists | Jun. 2012 | Pharmacists | Fact Sheet | 12.6 | 2 | 10.5 | 8 | 20.5 |
| AZ\_4 | Arizona | EPT Fact Sheet for Medical Providers | May 2016 | Medical Providers | Fact Sheet | 11.6 | 2 | 10.5 | 9.5 | 22 |
| AZ\_5 | Arizona | Partner Treatment for Chlamydia | May 2016 | Sex Partners | Fact Sheet | 8.9 | 4 | 9 | 6 | 19 |
| AZ\_6 | Arizona | EPT for Chlamydia and Gonorrhea: FAQs for Medical Professionals | Jun. 2012 | Medical Providers | Fact Sheet | 12.0 | 2 | 10 | 8.5 | 20.5 |
| AZ\_7 | Arizona | EPT for Chlamydia and Gonorrhea in AZ - A Clinical Tool | Jan. 2009 | Medical Providers | Fact Sheet | 11.8 | 2 | 7 | 11.5 | 20.5 |
| CA\_1 | California | PDPT for Chlamydia, Gonorrhea, and Trichomoniasis: Guidance for Medical Providers in CA | Jan. 2016 | Medical Providers | Implementation Guide | 12.1 | 2 | 10 | 21.5 | 33.5 |
| CA\_2 | California | Standard of Care for Patients with Chlamydia and Gonorrhea: EPT | Jul. 2016 | Medical Providers | Fact Sheet | 12.0 | 2 | 10 | 11 | 23 |
| CA\_3 | California | Directions for Sex Partners of Persons with Chlamydia | Jan. 2013 | Sex Partners | Directions | 8.4 | 4 | 9 | 10 | 23 |
| CT\_1 | Connecticut | Clinical Advisory: EPT for Chlamydia and Gonorrhea Infection in CT | Nov. 2014 | Medical Providers | Implementation Guide | 13.9 | 1 | 9.5 | 14 | 24.5 |
| CT\_2 | Connecticut | Partner Treatment for Chlamydia | - | Sex Partners | Directions | 8.8 | 4 | 11 | 10.5 | 25.5 |
| DC\_1 | District of Columbia | Safe, Effective Treatment for Patients and Their Sexual Partners: EPT Therapy Provider Guide | - | Medical Providers | Implementation Guide | 11.8 | 2 | 9.5 | 20 | 31.5 |
| DE\_1 | Delaware | EPT Information for Partners | - | Sex Partners | Directions | 10.8 | 3 | 10 | 6 | 19 |
| DE\_2 | Delaware | Important Counseling Messages for Those Treated by EPT | - | Sex Partners | Fact Sheet | 12.7 | 2 | 7.5 | 2 | 11.5 |
| HI\_1 | Hawaii | EPT for Chlamydia | - | Sex Partners | Directions | 10.0 | 4 | 9 | 12.5 | 25.5 |
| HI\_2 | Hawaii | EPT for Chlamydia and Gonorrhea | - | Sex Partners | Directions | 10.0 | 4 | 8.5 | 12.5 | 25 |
| IA\_1 | Iowa | IA DPH Recommendations for EPT of STIs | May 2016 | Medical Providers | Implementation Guide | 11.5 | 3 | 10.5 | 17.5 | 31 |
| IA\_2 | Iowa | IA Directions for Partners of Persons with Chlamydia | May 2016 | Sex Partners | Directions | 9.3 | 4 | 9 | 8 | 21 |
| IL\_1 | Illinois | EPT for Chlamydia and Gonorrhea: Guidance for Health Care Professionals in IL | Nov. 2011 | Medical Providers | Implementation Guide | 12.9 | 2 | 10 | 19.5 | 31.5 |
| IL\_2 | Illinois | EPT for Chlamydia and Gonorrhea Fact Sheet for HCPs | - | Medical Providers | Fact Sheet | 10.6 | 3 | 10.5 | 14 | 27.5 |
| IL\_3 | Illinois | Treatment Fact Sheet for Sex Partners of Persons with Chlamydia and Gonorrhea | - | Sex Partners | Directions | 9.5 | 4 | 8 | 11.5 | 23.5 |
| IL\_4 | Illinois | Treatment Fact Sheet for Sex Partners of Persons with Chlamydia | - | Sex Partners | Directions | 9.6 | 4 | 8 | 12 | 24 |
| IN\_1 | Indiana | EPT Physician's Guide | - | Medical Providers | Implementation Guide | 11.8 | 2 | 11 | 13 | 26 |
| IN\_2 | Indiana | EPT for Chlamydia and Gonorrhea: Guidance for Health Care Professionals in IN | - | Medical Providers | Implementation Guide | 11.0 | 3 | 11 | 18 | 32 |
| IN\_3 | Indiana | EPT for Chlamydia and Gonorrhea: FAQs | - | Medical Providers | Fact Sheet | 14.7 | 1 | 9.5 | 8.5 | 19 |
| IN\_4 | Indiana | Treatment Fact Sheet for Partners of Persons with Chlamydia | - | Sex Partners | Directions | 9.8 | 4 | 9 | 12 | 25 |
| IN\_5 | Indiana | Treatment Fact Sheet for Partners of Persons with Chlamydia and Gonorrhea | - | Sex Partners | Directions | 9.8 | 4 | 9 | 12 | 25 |
| LA\_1 | Louisiana | Screening for Chlamydia/Gonorrhea & Other STDs | Jul. 2011 | Medical Providers | Implementation Guide | 11.8 | 2 | 8 | 18.5 | 28.5 |
| MA\_1 | Massachusetts | Filling a Prescription for EPT | May 2015 | Pharmacists | Directions | 9.3 | 3 | 8.5 | 5 | 16.5 |
| MA\_2 | Massachusetts | Utilizing EPT for Chlamydia Infection in MA | Aug. 2011 | Medical Providers | Implementation Guide | 11.3 | 3 | 10 | 15 | 28 |
| MA\_3 | Massachusetts | A Message for Partners about Chlamydia | Aug. 2011 | Sex Partners | Directions | 8.8 | 4 | 11 | 10.5 | 25.5 |
| MA\_4 | Massachusetts | Guidance for Filling EPT Prescriptions | - | Pharmacists | Directions | 9.9 | 3 | 10 | 6.5 | 19.5 |
| MD\_1 | Maryland | EPT for Chlamydia and Gonorrhea: Guide for HCPs in MD | Jun. 2016 | Medical Providers | Implementation Guide | 10.2 | 3 | 10.5 | 22.5 | 36 |
| MD\_2 | Maryland | EPT for Chlamydia and Gonorrhea in MD | Feb. 2016 | Medical Providers | Fact Sheet | 11.6 | 2 | 10 | 5 | 17 |
| MD\_3 | Maryland | EPT in MD | May 2015 | Medical Providers | Fact Sheet | 11.6 | 2 | 10.5 | 6 | 18.5 |
| MD\_4 | Maryland | Patient Information: Chlamydia Treatment for Your Partners | Sep. 2017 | Index Patient | Directions | 7.4 | 4 | 11.5 | 14 | 29.5 |
| MD\_5 | Maryland | Chlamydia Information for Partners | Sep. 2017 | Sex Partners | Directions | 8.0 | 4 | 11.5 | 12 | 27.5 |
| MD\_6 | Maryland | EPT for Chlamydia, Gonorrhea, and Trichomoniasis: Fact Sheet for HCPs in MD | Mar. 2019 | Medical Providers | Fact Sheet | 13.2 | 1 | 8.5 | 11 | 20.5 |
| ME\_1 | Maine | EPT FAQs | Nov. 2015 | Medical Providers | Fact Sheet | 13.6 | 2 | 9.5 | 15.5 | 27 |
| ME\_2 | Maine | EPT Guide for Patients | Nov. 2015 | Index Patient | Directions | 10.3 | 3 | 9.5 | 15 | 27.5 |
| ME\_3 | Maine | EPT: A Guide for Sex Partners - Chlamydia & Azithromycin | Nov. 2015 | Sex Partners | Directions | 10.0 | 4 | 9 | 13.5 | 26.5 |
| ME\_4 | Maine | EPT: A Guide for Sex Partners - Chlamydia & Doxycycline | Nov. 2015 | Sex Partners | Directions | 9.8 | 4 | 9 | 13.5 | 26.5 |
| ME\_5 | Maine | EPT: Azithromycin Treatment Instructions | Nov. 2015 | Sex Partners | Directions | 10.8 | 3 | 9 | 7 | 19 |
| ME\_6 | Maine | EPT: Doxycycline Treatment Instructions | Nov. 2015 | Sex Partners | Directions | 10.4 | 3 | 9 | 6.5 | 18.5 |
| ME\_7 | Maine | Rules Governing the Implementation of EPT | Nov. 2015 | Medical Providers | Implementation Guide | 15.2 | 1 | 11 | 19 | 31 |
| MI\_1 | Michigan | Guidance for HCPs: EPT for Chlamydia and Gonorrhea | Jul. 2015 | Medical Providers | Implementation Guide | 11.2 | 3 | 10 | 18 | 31 |
| MI\_2 | Michigan | EPT: Information Sheet for Patients and Partners | - | Index Patient and Sex Partners | Directions | 11.9 | 3 | 9.5 | 13 | 25.5 |
| MI\_3 | Michigan | Summary EPT Clinical Guidelines for Chlamydia and Gonorrhea: Pharmacy Information | Jan. 2015 | Pharmacists | Directions | 13.2 | 2 | 11 | 9.5 | 22.5 |
| MN\_1 | Minnesota | Directions for Sex Partners of Persons with Chlamydia | Mar. 2007 | Sex Partners | Directions | 9.5 | 4 | 9 | 9.5 | 22.5 |
| MN\_2 | Minnesota | Directions for Sex Partners of Persons with Gonorrhea and Chlamydia | Mar. 2007 | Sex Partners | Directions | 10.3 | 3 | 9 | 9 | 21 |
| MN\_3 | Minnesota | Partner Information | May 2018 | Sex Partners | Directions, Trifold Brochure | 8.8 | 4 | 10.5 | 9 | 23.5 |
| MT\_1 | Montana | Patient Delivered Partner Therapy: Clinical Protocol Manual | Oct. 2017 | Medical Providers | Implementation Guide | 9.7 | 3 | 9.5 | 9.5 | 22 |
| ND\_1 | North Dakota | EPT Clinical Protocol Manual | Apr. 2018 | Medical Providers | Implementation Guide | 11.7 | 2 | 8.5 | 11 | 21.5 |
| NH\_1 | New Hampshire | EPT Guide for HCPs | Aug. 2017 | Medical Providers | Fact Sheet | 12.2 | 2 | 9 | 13.5 | 24.5 |
| NH\_2 | New Hampshire | EPT Guide for Patients | Aug. 2017 | Index Patient | Fact Sheet | 11.0 | 3 | 8 | 14.5 | 25.5 |
| NH\_3 | New Hampshire | EPT Guide for Sex Partners | Aug. 2017 | Sex Partners | Fact Sheet | 12.6 | 2 | 9 | 13 | 24 |
| NJ\_1 | New Jersey | EPT in NJ | - | Medical Providers | Fact Sheet | 14.3 | 1 | 7.5 | 4 | 12.5 |
| NM\_1 | New Mexico | NM DoH Guidelines for EPT of STDs | - | Medical Providers | Implementation Guide | 12.9 | 2 | 9.5 | 16 | 27.5 |
| NM\_2 | New Mexico | Directions for Taking Azithromycin | - | Sex Partners | Directions | 9.6 | 4 | 10 | 11.5 | 25.5 |
| NY\_1 | New York | EPT: Limiting the Spread of Chlamydia in NYS | Jan. 2017 | Index Patient | Fact Sheet, Trifold Brochure | 9.6 | 4 | 11 | 7.5 | 22.5 |
| NY\_2 | New York | EPT: A Guide for Partner Care | Jan. 2017 | Sex Partners | Fact Sheet | 9.1 | 4 | 11 | 14 | 29 |
| NY\_3 | New York | EPT: A Summary for HCPs | Nov. 2018 | Medical Providers | Fact Sheet | 11.4 | 3 | 10.5 | 15.5 | 29 |
| NY\_4 | New York | EPT Guidelines for HCPs in NYS | - | Medical Providers | Implementation Guide | 11.5 | 3 | 10 | 21 | 34 |
| NY\_5 | New York | EPT FAQs for Pharmacists NYS | Mar. 2017 | Pharmacists | Fact Sheet | 13.2 | 2 | 9 | 11.5 | 22.5 |
| OK\_1 | Oklahoma | EPT: Client Delivered Partner Therapy for Gonococcal and Chlamydial Infections | Jan. 2018 | Medical Providers | Implementation Guide | 12.0 | 2 | 8.5 | 10.5 | 21 |
| OR\_1 | Oregon | EPT for STDs: Protocol for HCPs in OR | Feb. 2015 | Medical Providers | Implementation Guide | 13.5 | 1 | 11 | 19 | 31 |
| OR\_2 | Oregon | EPT in OR FAQs | Feb. 2015 | Medical Providers | Fact Sheet | 13.3 | 2 | 9 | 1 | 12 |
| OR\_3 | Oregon | You've Been Exposed to Chlamydia: Now What | Feb. 2015 | Sex Partners | Directions | 9.3 | 4 | 10.5 | 12.5 | 27 |
| RI\_1 | Rhode Island | EPT for STDSs: Guidance for Medical Providers in RI | Oct. 2011 | Medical Providers | Implementation Guide | 11.8 | 2 | 9 | 18 | 29 |
| TX\_1 | Texas | EPT in TX | May 2018 | Medical Providers | Fact Sheet | 13.3 | 2 | 10 | 8.5 | 20.5 |
| TX\_2 | Texas | PDPT for Chlamydia | - | Sex Partners | Directions | 10.7 | 3 | 9 | 13 | 25 |
| TX\_3 | Texas | Expedited STD Management Implementation Guide | Jan. 2019 | Medical Providers | Implementation Guide | 11.1 | 3 | 10 | 19 | 32 |
| VT\_1 | Vermont | Treatment Standards for EPT for STDs | Jul. 2014 | Medical Providers | Fact Sheet | 13.3 | 1 | 9.5 | 6 | 16.5 |
| WA\_1 | Washington | WA DoH Background and Recommendations for Incorporating PDPT by HCPs | - | Medical Providers | Fact Sheet | 16.3 | 0 | 9.5 | 12.5 | 22 |
| WA\_2 | Washington | Directions for Taking Chlamydia Medicine | - | Sex Partners | Directions | 10.6 | 3 | 8.5 | 8.5 | 20 |
| WI\_1 | Wisconsin | EPT for Chlamydia, Gonorrhea, and Trichomoniasis: Guidance for HCPs in WI | May 2013 | Medical Providers | Implementation Guide | 13.0 | 2 | 9.5 | 22.5 | 34 |
| WI\_2 | Wisconsin | Chlamydia Treatment Information | Jun. 2010 | Sex Partners | Directions | 10.5 | 3 | 9 | 11 | 23 |
| WI\_3 | Wisconsin | FAQs by Pharmacists | - | Pharmacists | Fact Sheet | 13.7 | 1 | 9.5 | 10 | 20.5 |
| WV\_1 | West Virginia | EPT for Chlamydia and Gonorrhea in WV | - | Medical Providers | Fact Sheet | 12.0 | 2 | 10.5 | 6 | 18.5 |
| WY\_1 | Wyoming | EPT Guidance | Nov. 2017 | Medical Providers | Fact Sheet | 9.4 | 3 | 9 | 10.5 | 22.5 |
| *\* Date of publication or revision. HCP=health care provider. aReadability assessed with Readable Pro, 4 possible points. bDesign assessed with MIDAS, 13 possible points. cContent assessed with content tools, 25 possible points for providers and pharmacists, 20 points for patients and partners.* |

# Appendix D. Evaluation Measure Results

|  |
| --- |
| **Table 1. Readability |** Average Readability for EPT Informational Material |
|  | **Index Patients & Sex Partners (n=35)** | **Medical Providers & Pharmacists (n=49)** | **All Audiences (N=84)** |
| **Flesch Kincaid Grade Level** | 7.75 (sd=1.27) | 10.86 (sd=1.21) | 9.57 (sd=1.97) |
| **Gunning Fog Score** | 10.58 (sd=1.19) | 12.61 (sd=1.91) | 11.77 (sd=1.92) |
| **SMOG Index** | 11.36 (sd=0.96) | 13.25 (sd=1.37) | 12.46 (sd=1.53) |
| **Average Reading Level** | 9.90 (sd=1.12) | 12.24 (sd=1.44) | 11.27 (sd=1.75) |

|  |
| --- |
| **Table 2. Design |** Documents Meeting MIDAS Criterion |
| **Criterion** | **n (%)** |
| Type size (≥10 point) | 82 (97.6%) |
| Serif style letters in text | 26 (31%) |
| Sharp ink contrast | 82 (97.6%) |
| Line spacing (≥2.2 mm) | 81 (96.4%) |
| Margins (≥0.5 in. sides and bottom; ≥.25 in. at the top) | 77 (91.7%) |
| True headings (separate line) | 74 (88.1%) |
| Upper and lower case in |  |
| Headings | 61 (72.6%) |
| Text | 84 (100%) |
| Line lengths (≤ 40 letters) | 2 (2.4%) |
| Bullet points | 70 (83.3%) |
| Bolding/box or summary to highlight important points | 45 (53.6%) |
| No watermarks under the text | 84 (100%) |
| Relevant pictures/illustrations | 11 (13.1%) |
| *Shading indicates that less than 50% of the documents fulfilled this criterion* |

|  |
| --- |
| **Table 3. Content |** Documents Meeting Medical Provider and Pharmacist Criterion |
| **Criterion** | **n (%)** |
| 1. Is the importance of partner mgmt./referral for STIs emphasized?
 | 36 (69.2%) |
| 1. Is Chlamydia described?
 | 4 (7.7%) |
| 1. Are the long-term effects of untreated Chlamydia described?
 | 9 (17.3%) |
| 1. Is EPT/PDPT defined?
 | 48 (92.3%) |
| 1. Is the effectiveness/are the benefits of EPT stated?
 | 33 (63.5%) |
| 1. Does the document make any statement about legality?
 | 41 (78.8%) |
| 1. Does the document make any statement about liability?
 | 17 (32.7%) |
| 1. Is the drug treatment for Chlamydia described?
 | 34 (65.7%) |
| 1. Is “recent sexual partner” defined as a partner within the past 60 days?
 | 24 (46.2%) |
| 1. Are eligibility criteria for EPT given?
 | 24 (46.2%) |
| 1. Are exclusion criteria for EPT given, i.e. when is EPT not recommended?
 | 18 (34.6%) |
| 1. Are directions given for the delivery method of EPT?
 | 38 (73.1%) |
| 1. Are directions given for the prescription instructions?
 | 23 (44.2%) |
| 1. Does the document make any reference to the cost of EPT, e.g. it’s free, will be covered by insurance, paid out of pocket, etc.?
 | 14 (26.9%) |
| 1. Advise [patient to tell] partners to seek medical evaluation, e.g. referral.
 | 25 (48.1%) |
| 1. Provide written EPT instructions for the patient/partner.
 | 41 (78.8%) |
| 1. Provide written information on allergies/possible adverse reactions.
 | 21 (40.4%\* |
| 1. Advise the patient/partner to abstain from vaginal, anal and oral sex for 7 days post-treatment.
 | 24 (46.2%) |
| 1. Advise the patient/partner be retested in 3 months.
 | 20 (38.5%) |
| 1. Present (written or oral) at least one STI prevention strategy.
 | 8 (15.4%) |
| 1. Are adolescent populations specifically mentioned?
 | 8 (15.4%) |
| 1. Are MSM populations specifically mentioned?
 | 31 (59.6%) |
| 1. Are pregnant populations specifically mentioned?
 | 19 (36.5%) |
| 1. Does the document mention a limit on how many EPT doses/prescriptions a doctor can provide to a patient?
 | 20 (38.5%) |
| 1. Are endorsements of EPT from medical associations and professional societies mentioned?
 | 12 (23.1%) |
| *Shading indicates that less than 50% of the documents fulfilled this criterion* |

|  |
| --- |
| **Table 4. Content |** Documents Meeting Index Patient and Sex Partner Criterion |
| **Criterion** | **n (%)** |
| 1. Does it explain why the patient/partner is receiving additional

medication/prescription, e.g. risk of exposure?  | 31 (81.6%) |
| 1. Is Chlamydia described?
 | 24 (63.2%) |
| 1. Are the symptoms of Chlamydia described?
 | 27 (71.1%) |
| 1. Does it state that Chlamydia may be asymptomatic?
 | 30 (78.9%) |
| 1. Are the long-term effects of untreated Chlamydia described?
 | 20 (52.6%) |
| 1. Is EPT/PDPT defined?
 | 12 (31.6%) |
| 1. Is the drug treatment for Chlamydia described?
 | 30 (78.9%) |
| 1. Is “recent sexual partner” defined as a partner within the past 60 days?
 | 8 (21.1%) |
| 1. Does the document make any reference to the cost of EPT, e.g. it’s free, will be covered by insurance, paid out of pocket, etc.?
 | 4 (10.5%) |
| 1. Does it include information on allergies/possible adverse reactions?
 | 29 (76.3%) |
| 1. Is there information about what to do in the case of an adverse event?
 | 26 (68.4%) |
| 1. Is it advised to abstain from vaginal, anal and oral sex for 7 days post-treatment?
 | 34 (89.5%) |
| 1. Is it advised to be to be retested in 3 months?
 | 17 (44.7%) |
| 1. Is at least one STI prevention strategy presented?
 | 22 (57.9%) |
| 1. Does it include sources for STI-related health care information?
 | 26 (68.4%) |
| 1. Does it mention the risk of intimate partner violence?
 | 3 (7.9%) |
| 1. Does it entail directions/advice on how to tell the partner about the diagnosis?
 | 3 (7.9%) |
| 1. Does it entail directions/advice on how to tell the partner about EPT?
 | 0 (0%) |
| 1. Is there information about what to do in the case that the partner refuses to take medicine or seek STI testing?
 | 3 (7.9%) |
| 1. Does it describe what to expect when picking up the prescription at a pharmacy?
 | 5 (13.2%) |
| *Shading indicates that less than 50% of the documents fulfilled this criterion* |

# Appendix E. Inter-Rater Reliability for Design and Content Tools

|  |
| --- |
| **Design (MIDAS) |** Percentage agreement by item |
| Item | %  |
| 1. Type size (≥10 point)
 | 98.62 |
| 1. Serif style letters in text
 | 94.05 |
| 1. Sharp ink contrast
 | 97.62 |
| 1. Line spacing (≥2.2 mm)
 | 97.62 |
| 1. Margins (≥0.5 in. sides and bottom; ≥.25 in. at the top)
 | 97.62 |
| 1. True headings (separate line)
 | 92.86 |
| 1. Upper and lower case in headings
 | 90.48 |
| 1. Upper and lower case in text
 | 100.00 |
| 1. Line lengths (≤ 40 letters)
 | 92.86 |
| 1. Bullet points
 | 92.86 |
| 1. Bolding/box or summary to highlight important points
 | 90.48 |
| 1. No watermarks under the text
 | 100.00 |
| 1. Relevant pictures/illustrations
 | 95.24 |
| **Average** | **95.33** |

|  |
| --- |
| **Content Tool for Medical Provider and Pharmacist |** Percentage agreement by item |
| Item | % |
| 1. Is the importance of partner mgmt./referral for STIs emphasized?
 | 88.00 |
| 1. Is Chlamydia described?
 | 92.00 |
| 1. Are the long-term effects of untreated Chlamydia described?
 | 84.00 |
| 1. Is EPT/PDPT defined?
 | 100.00 |
| 1. Is the effectiveness/are the benefits of EPT stated?
 | 92.00 |
| 1. Does the document make any statement about legality?
 | 92.00 |
| 1. Does the document make any statement about liability?
 | 96.00 |
| 1. Is the drug treatment for Chlamydia described?
 | 98.00 |
| 1. Is “recent sexual partner” defined as a partner within the past 60 days?
 | 100.00 |
| 1. Are eligibility criteria for EPT given?
 | 90.00 |
| 1. Are exclusion criteria for EPT given, i.e. when is EPT not recommended?
 | 90.00 |
| 1. Are directions given for the delivery method of EPT?
 | 94.00 |
| 1. Are directions given for the prescription instructions?
 | 98.00 |
| 1. Does the document make any reference to the cost of EPT, e.g. it’s free, will be covered by insurance, paid out of pocket, etc.?
 | 98.00 |
| 1. Advise [patient to tell] partners to seek medical evaluation, e.g. referral.
 | 92.00 |
| 1. Provide written EPT instructions for the patient/partner.
 | 96.00 |
| 1. Provide written information on allergies/possible adverse reactions.
 | 82.00 |
| 1. Advise the patient/partner to abstain from vaginal, anal and oral sex for 7 days post-treatment.
 | 98.00 |
| 1. Advise the patient/partner be retested in 3 months.
 | 98.00 |
| 1. Present (written or oral) at least one STI prevention strategy.
 | 90.00 |
| 1. Are adolescent populations specifically mentioned?
 | 94.00 |
| 1. Are MSM populations specifically mentioned?
 | 96.00 |
| 1. Are pregnant populations specifically mentioned?
 | 96.00 |
| 1. Does the document mention a limit on how many EPT doses/prescriptions a doctor can provide to a patient?
 | 96.00 |
| 1. Are endorsements of EPT from medical associations and professional societies mentioned?
 | 86.00 |
| **Average** | **93.44** |

|  |
| --- |
| **Content Tool for Index Patient and Sex Partner |** Percentage agreement by item |
| Item | % |
| 1. Does it explain why the patient/partner is receiving additional medication / prescription, e.g. risk of exposure?
 | 91.43 |
| 1. Is Chlamydia described?
 | 82.86 |
| 1. Are the symptoms of Chlamydia described?
 | 97.14 |
| 1. Does it state that Chlamydia may be asymptomatic?
 | 88.57 |
| 1. Are the long-term effects of untreated Chlamydia described?
 | 85.71 |
| 1. Is EPT/PDPT defined?
 | 100.00 |
| 1. Is the drug treatment for Chlamydia described?
 | 100.00 |
| 1. Is “recent sexual partner” defined as a partner within the past 60 days?
 | 94.29 |
| 1. Does the document make any reference to the cost of EPT, e.g. it’s free, will be covered by insurance, paid out of pocket, etc.?
 | 85.71 |
| 1. Does it include information on allergies/possible adverse reactions?
 | 94.29 |
| 1. Is there information about what to do in the case of an adverse event?
 | 85.71 |
| 1. Is it advised to abstain from vaginal, anal and oral sex for 7 days post-treatment?
 | 94.29 |
| 1. Is it advised to be to be retested in 3 months?
 | 94.29 |
| 1. Is at least one STI prevention strategy presented?
 | 97.14 |
| 1. Does it include sources for STI-related health care information?
 | 80.00 |
| 1. Does it mention the risk of intimate partner violence?
 | 100.00 |
| 1. Does it entail directions/advice on how to tell the partner about the diagnosis?
 | 100.00 |
| 1. Does it entail directions/advice on how to tell the partner about EPT?
 | 88.57 |
| 1. Is there information about what to do in the case that the partner refuses to take medicine or seek STI testing?
 | 100.00 |
| 1. Does it describe what to expect when picking up the prescription at a pharmacy?
 | 97.14 |
| **Average** | **93.86** |

# Appendix F. Document Rankings

|  |
| --- |
| **Top 10% Readability** |
| **Document** | **Score** |
| AK\_1 | A (4.0) |
| AK\_2 | A (4.0) |
| AZ\_5 | A (4.0) |
| CA\_3 | A (4.0) |
| CT\_2 | A (4.0) |
| HI\_1 | A (4.0) |
| HI\_2 | A (4.0) |
| IA\_2 | A (4.0) |
| IL\_3 | A (4.0) |
| IL\_4 | A (4.0) |
| IN\_4 | A (4.0) |
| IN\_5 | A (4.0) |
| MA\_3 | A (4.0) |
| MD\_4 | A (4.0) |
| MD\_5 | A (4.0) |
| ME\_3 | A (4.0) |
| ME\_4 | A (4.0) |
| MN\_1 | A (4.0) |
| MN\_3 | A (4.0) |
| NM\_2 | A (4.0) |
| NY\_1 | A (4.0) |
| NY\_2 | A (4.0) |
| OR\_3 | A (4.0) |

|  |
| --- |
| **Top 10% Design** |
| **Document** | **Score** |
| MD\_4 | 11.5 |
| MD\_5 | 11.5 |
| CT\_2 | 11 |
| IN\_1 | 11 |
| IN\_2 | 11 |
| MA\_3 | 11 |
| ME\_7 | 11 |
| MI\_3 | 11 |
| NY\_1 | 11 |
| NY\_2 | 11 |
| OR\_1 | 11 |

|  |
| --- |
| **Top 10% Content**Medical Provider and Pharmacist |
| **Document** | **Score** |
| MD\_1 | 22.5 |
| WI\_1 | 22.5 |
| CA\_1 | 21.5 |
| NY\_4 | 21 |

|  |
| --- |
| **Top 10% Content** Index Patient and Sex Partner |
| **Document** | **Score** |
| ME\_2 | 15 |
| NH\_2 | 14.5 |
| MD\_4 | 14 |
| NY\_2 | 14 |

|  |
| --- |
| **Overall Top 10% |** Medical Provider and Pharmacist |
| **Document** | **Readability\*a** | **Designb** | **Contentc** | **Total Score** |
| MD\_1 | 3 | 10.5 | 22.5 | 36 |
| NY\_4 | 3 | 10 | 21 | 34 |
| WI\_1 | 2 | 9.5 | 22.5 | 34 |
| CA\_1 | 2 | 10 | 21.5 | 33.5 |
| *\* Letter grades were converted to their numeric equivalent on a 4.0 scale (“A”=4, “B” =3, “C”=2, “D”=1, “E”=0). aReadability assessed with Readable Pro, 4 possible points. bDesign assessed with MIDAS, 13 possible points. cContent assessed with content tool, 25 possible points for providers and pharmacists.* |

|  |
| --- |
| **Overall Top 10% |** Index Patient and Sex Partner |
| **Document** | **Readability\*a** | **Designb** | **Contentc** | **Total Score** |
| MD\_4 | 4 | 11.5 | 14 | 29.5 |
| NY\_2 | 4 | 11 | 14 | 29 |
| MD\_5 | 4 | 11.5 | 12 | 27.5 |
| ME\_2 | 3 | 9.5 | 15 | 27.5 |
| *Letter grades were converted to their numeric equivalent on a 4.0 scale (“A”=4, “B” =3, “C”=2, “D”=1, “E”=0). aReadability assessed with Readable Pro, 4 possible points.* *bDesign assessed with MIDAS, 13 possible points. cContent assessed with content tool, 20 points for patients and partners.* |